All In Biotech

Drug Trial Radar · NCT04167553

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

A Phase 1, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Aug 30, 2019

Primary completion

Dec 9, 2020

Study completion Dec 9, 2020

Sponsor

Sponsor type
Industry
First posted
Nov 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.

Conditions

  • Obese With Comorbidities
  • Overweight With Comorbidities
  • Type2 Diabetes

Interventions

  • HM15136Drug

    In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional. In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.

  • PlaceboDrug

    In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional. In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Evaluate the Incidence of AEsTime frame: after multiple subcutaneous (SC) doses for 12 weeks
  2. To Evaluate Serum Amylase Levels at 12 WeeksTime frame: after multiple subcutaneous (SC) doses for 12 weeks
  3. Change From Baseline in Tympanic TemperatureTime frame: after multiple subcutaneous (SC) doses for 12 weeks
  4. Change From Baseline in 12-lead ECG ParametersTime frame: after multiple subcutaneous (SC) doses for 12 weeks
  5. Injection Site ReactionsTime frame: after multiple subcutaneous (SC) doses for 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prosciento

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.